371 active trials 188 recruiting 93 Phase 3 59 disease areas 87 changes in 30 days
49 trials changed in the last 30 days: 0 stopped, 18 with notable changes, 31 with minor changes only.
Primary completion pushed from Aug 2, 2028 to Jan 29, 2029
Also in this update: Enrollment increased: 104 → 140 participants; Completion pushed from Sep 30, 2030 to Jun 18, 2031
Novartis PharmaceuticalsPhase 2 NCT06997588 Registry history of NCT06997588 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Feb 22, 2036 to Apr 18, 2039
Also in this update: Enrollment reduced: 1400 → 1105 participants
Novartis PharmaceuticalsPhase 3 NCT02445222 Registry history of NCT02445222 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Apr 8, 2030 to Apr 3, 2034
Also in this update: Trial sites expanded: 143 → 162 locations; Completion pushed from Apr 5, 2032 to Oct 2, 2034
Novartis PharmaceuticalsPhase 3 NCT06133972 Registry history of NCT06133972 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from May 9, 2028 to Jan 18, 2029
Novartis PharmaceuticalsPhase 2 NCT07421167 Registry history of NCT07421167 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jun 27, 2031 to Mar 23, 2032
Also in this update: Completion pushed from Jul 25, 2031 to Apr 20, 2032
Novartis PharmaceuticalsPhase 2 NCT07679269 Registry history of NCT07679269 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Interventions modified
Novartis PharmaceuticalsPhase 1/2 NCT07190300 Registry history of NCT07190300 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment reopened
Also in this update: Enrollment increased: 448 → 540 participants; Trial sites expanded: 155 → 161 locations
Novartis PharmaceuticalsPhase 3 NCT04557462 Registry history of NCT04557462 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Start date changed from estimate of Nov 9, 2026 to Sep 21, 2026; Primary and study completion moved earlier from Jul 17, 2028 to Jun 2, 2028
Novartis PharmaceuticalsPhase 3 NCT07816328 Registry history of NCT07816328 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 0 → 3 locations
Novartis PharmaceuticalsPhase 2 NCT07748624 Registry history of NCT07748624 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Primary and study completion pushed from Sep 16, 2027 to Oct 19, 2027; Start date changed from estimate of Nov 9, 2026 to Sep 18, 2026
Novartis PharmaceuticalsPhase 2 NCT07830719 Registry history of NCT07830719 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Novartis PharmaceuticalsPhase 4 NCT07448610 Registry history of NCT07448610 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Novartis PharmaceuticalsPhase 2 NCT07801495 Registry history of NCT07801495 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Novartis PharmaceuticalsPhase 1 NCT07783503 Registry history of NCT07783503 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Start date changed from estimate of Sep 21, 2026 to Sep 22, 2026; and 1 more change in the last 30 days
Novartis PharmaceuticalsNot specified NCT07598448 Registry history of NCT07598448 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Start date changed from estimate of Aug 20, 2026 to Aug 25, 2026
Novartis PharmaceuticalsNot specified NCT07737756 Registry history of NCT07737756 on ClinicalTrials.gov (opens the registry)
Updated
Results posted: Oct 6, 2026
Novartis PharmaceuticalsPhase 4 NCT04230148 Registry history of NCT04230148 on ClinicalTrials.gov (opens the registry)
Updated
Results posted: Oct 2, 2026
Novartis PharmaceuticalsPhase 4 NCT05110196 Registry history of NCT05110196 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion moved earlier from Nov 8, 2028 to Aug 10, 2027
Novartis PharmaceuticalsPhase 1 NCT05739942 Registry history of NCT05739942 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 246 participants (planned 340)
Novartis PharmaceuticalsPhase 3 NCT06813911 Registry history of NCT06813911 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 25 participants (planned 40)
Novartis PharmaceuticalsPhase 1/2 NCT07468071 Registry history of NCT07468071 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 130 → 120 locations
Novartis PharmaceuticalsPhase 3 NCT06744920 Registry history of NCT06744920 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Feb 13, 2032 to Mar 15, 2032
Also in this update: Completion pushed from Sep 4, 2035 to Oct 4, 2035
Novartis PharmaceuticalsPhase 2 NCT06991556 Registry history of NCT06991556 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Novartis PharmaceuticalsPhase 1/2 NCT05798117 Registry history of NCT05798117 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 670 participants (planned 600)
Novartis PharmaceuticalsNot specified NCT05217810 Registry history of NCT05217810 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 24, 2026 to Dec 8, 2026
Novartis PharmaceuticalsPhase 1 NCT07465653 Registry history of NCT07465653 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Oct 16, 2026 to Mar 30, 2027
Novartis PharmaceuticalsNot specified NCT07454850 Registry history of NCT07454850 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 206 → 236 participants
Novartis PharmaceuticalsPhase 2 NCT04589650 Registry history of NCT04589650 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 120 → 152 participants
Also in this update: Trial sites expanded: 3 → 6 locations
Novartis PharmaceuticalsPhase 1 NCT07626281 Registry history of NCT07626281 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 118 → 125 locations
And 8 more changes in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT07357727 Registry history of NCT07357727 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 10 → 13 locations
Novartis PharmaceuticalsPhase 1/2 NCT06546670 Registry history of NCT06546670 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 65 → 69 locations
Novartis PharmaceuticalsNot specified NCT07549516 Registry history of NCT07549516 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 89 → 82 locations
Novartis PharmaceuticalsNot specified NCT06551519 Registry history of NCT06551519 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 20 → 34 locations
Novartis PharmaceuticalsPhase 3 NCT07665437 Registry history of NCT07665437 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 19 → 26 locations
Novartis PharmaceuticalsPhase 3 NCT07621809 Registry history of NCT07621809 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 5 → 13 locations
Novartis PharmaceuticalsPhase 3 NCT07700056 Registry history of NCT07700056 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 10 → 14 locations
Novartis PharmaceuticalsPhase 3 NCT07768371 Registry history of NCT07768371 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 1 → 4 locations
Novartis PharmaceuticalsPhase 3 NCT07811869 Registry history of NCT07811869 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 81 → 93 locations
Novartis PharmaceuticalsPhase 2/3 NCT06780670 Registry history of NCT06780670 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 82 → 117 locations
Novartis PharmaceuticalsPhase 3 NCT07326709 Registry history of NCT07326709 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 95 → 100 locations
Novartis PharmaceuticalsPhase 3 NCT06855277 Registry history of NCT06855277 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 9 → 12 locations
Novartis PharmaceuticalsPhase 3 NCT07498335 Registry history of NCT07498335 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 9 → 18 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 2 NCT07775924 Registry history of NCT07775924 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 9 → 20 locations
Novartis PharmaceuticalsPhase 2 NCT07737743 Registry history of NCT07737743 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 4 → 7 locations
Novartis PharmaceuticalsPhase 2 NCT07681271 Registry history of NCT07681271 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 5 → 9 locations
Novartis PharmaceuticalsPhase 1 NCT07570979 Registry history of NCT07570979 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Dec 31, 2026 to Oct 28, 2026
Novartis PharmaceuticalsPhase 2 NCT05445843 Registry history of NCT05445843 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Nov 1, 2031 to Oct 1, 2031
Novartis PharmaceuticalsPhase 1/2 NCT04925479 Registry history of NCT04925479 on ClinicalTrials.gov (opens the registry)
Updated
Start date pushed from Sep 15, 2026 to Sep 30, 2026
Novartis PharmaceuticalsNot specified NCT07465666 Registry history of NCT07465666 on ClinicalTrials.gov (opens the registry)
Updated
Start date changed from estimate of Sep 22, 2026 to Sep 8, 2026
Novartis PharmaceuticalsPhase 1 NCT07801508 Registry history of NCT07801508 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-09 | NCT07868328 A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary… | Phase 2 | Not Yet Recruiting |
| 2026-10-02 | NCT07855276 A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to… | Phase 1 | Not Yet Recruiting |
| 2026-09-30 | NCT07850752 A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With… | Phase 3 | Not Yet Recruiting |
| 2026-09-28 | NCT07843758 An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant… | Completed | |
| 2026-09-28 | NCT07844070 A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During… | Active, Not Recruiting | |
| 2026-09-24 | NCT07839858 A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment… | Completed | |
| 2026-09-21 | NCT07830719 Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With… | Phase 2 | Recruiting |
| 2026-09-15 | NCT07821411 A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | Active, Not Recruiting |
| Phase 1 | 43 | |
| Phase 1/2 | 26 | |
| Phase 2 | 71 | |
| Phase 2/3 | 2 | |
| Phase 3 | 91 | |
| Phase 4 | 25 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | Melanoma | Recruiting | 2026-10-09 |
| NCT04638647 | Secukinumab Open Label Roll-over Extension Protocol | Autoimmunity, Inflammation | Recruiting | 2026-09-28 |
| NCT07448610 | ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants… | Spinal Muscular Atrophy | Recruiting | 2026-09-18 |
| NCT07489573 | Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to… | Hidradenitis Suppurativa (HS) | Recruiting | 2026-09-09 |
| NCT04877522 | Asciminib Roll-over Study | Chronic Myelogenous Leukemia | Recruiting | 2026-07-06 |
| NCT04480853 | Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing… | Multiple Sclerosis | Recruiting | 2026-06-26 |
| NCT04657822 | Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior… | Sickle Cell Disease | Recruiting | 2026-06-08 |
| NCT06824103 | Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With… | Graft vs. Host Disease | Recruiting | 2026-06-08 |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate… | Prostate Cancer | Recruiting | 2026-06-04 |
| NCT06733922 | ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS | Relapsing Remitting Multiple Sclerosis (RRMS) | Recruiting | 2026-05-15 |
| NCT07034690 | Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in… | Atherosclerotic Cardiovascular Disease | Recruiting | 2026-05-04 |
| NCT06501443 | LATAM LOWERS LDL-C | Hypercholesterolaemia | Recruiting | 2025-12-30 |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | Metastatic Breast Cancer | Active, Not Recruiting | 2026-10-09 |
| NCT02584933 | Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib… | ALK Positive Malignancies | Active, Not Recruiting | 2026-09-17 |
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous… | Renal Angiomyolipoma | Active, Not Recruiting | 2026-09-17 |
| NCT06462469 | Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV… | Steroid-refractory Acute Graft Versus Host Disease | Active, Not Recruiting | 2026-09-17 |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | Diffuse Astrocytoma | Active, Not Recruiting | 2026-08-27 |
| NCT05622708 | A Study of Secukinumab to Evaluate Maintenance of Response in Participants With… | Non-radiographic Axial Spondyloarthritis | Active, Not Recruiting | 2026-08-21 |
| NCT02386800 | CINC424A2X01B Rollover Protocol | Primary Myelofibrosis | Active, Not Recruiting | 2026-08-20 |
| NCT06444113 | Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of… | Multiple Sclerosis | Active, Not Recruiting | 2026-08-12 |
| NCT06372925 | Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute… | Plaque, Atherosclerotic | Active, Not Recruiting | 2026-07-28 |
| NCT07713602 | Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in… | Malaria | Not Yet Recruiting | 2026-07-20 |
| NCT07684469 | Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care… | Acute Coronary Syndrome | Not Yet Recruiting | 2026-07-06 |
| NCT05090371 | A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After… | Relapsing-Remitting Multiple Sclerosis | Active, Not Recruiting | 2026-05-29 |
| NCT06941792 | Inclisiran Effectiveness in China: a Pragmatic Randomized Trial | Coronary Heart Disease | Active, Not Recruiting | 2026-05-29 |
Breast Cancer (33) · Prostate Cancer (32) · Multiple Sclerosis (27) · Leukemia (25) · Lung Cancer (19) · Non-Small Cell Lung Cancer (NSCLC) (17) · Hidradenitis Suppurativa (16) · Chronic Myeloid Leukemia (CML) (14) · Heart Disease (10) · Lupus (SLE) (9)